Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL682111 | 0.80 | PARP1 (0.34) | ALDH1A1 | |
| SCHEMBL1683179 | 0.75 | SLC6A2 (0.34) | — | |
| Hydrochloric Acid SCHEMBL23536059 | 0.74 | SLC6A2 (0.33) | — | |
| Aziridine SCHEMBL27886085 | 0.73 | ALDH1A1 (0.42) | ALDH1A1 | |
| SCHEMBL17888741 | 0.73 | — | — | |
| SCHEMBL761610 | 0.72 | EPHX1 (0.38) | ALDH1A1 | |
| SCHEMBL15475655 | 0.72 | ADRA2A (0.31) | ALDH1A1 | |
| SCHEMBL10435676 | 0.72 | ATP1A1 (0.32) | ALDH1A1 | |
| Piperazine SCHEMBL16211222 | 0.71 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL23558953 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104583214-B | The inhibitor of human immunodeficiency virus replication | 百时美施贵宝公司 | 2017-06-09 | — | — | CN | disclosed |
| EP-2888266-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO 5) LTD (GB) | 2017-01-11 | — | — | EP | disclosed |
| EP-2888266-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO 5) LTD (GB) | 2017-01-11 | — | — | EP | disclosed |
| EP-2888266-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | Bristol-Myers Squibb Company (US) | 2015-07-01 | — | — | EP | disclosed |
| CN-104583214-A | Inhibitors of human immunodeficiency virus replication | BRISTOL MYERS SQUIBB CO | 2015-04-29 | — | — | CN | disclosed |
| US-8906929-B2 | Inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906929-B2 | Inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906929-B2 | Inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140051692-A1 | Inhibitors of Human Immunodeficiency Virus Replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2014-02-20 | — | — | US | disclosed |
| US-20140051692-A1 | Inhibitors of Human Immunodeficiency Virus Replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2014-02-20 | — | — | US | disclosed |
| US-20140051692-A1 | Inhibitors of Human Immunodeficiency Virus Replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2014-02-20 | — | — | US | disclosed |
| WO-2014028384-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-20 | — | — | WO | disclosed |
| WO-2014028384-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051692-A1 | Inhibitors of Human Immunodeficiency Virus Replication | EIF2AK2, RTF2, MAVS | ALDH1A1 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.